Last reviewed · How we verify
Generic clopidogrel
At a glance
| Generic name | Generic clopidogrel |
|---|---|
| Sponsor | Hospital Central San Luis Potosi, Mexico |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- P2Y12 Inhibitor Monotherapy Versus Extended DAPT in Patients Treated With Bioresorbable Scaffold (PHASE4)
- Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence
- Fasted Bioequivalence Study of Clopidogrel Film-coated Tablets, 75 mg in 48 Healthy, Adult Male and Female Subjects. (PHASE1)
- Assessment of Loading With the P2Y12 Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting (PHASE3)
- Efficacy and Tolerability of Clopidogrel Resinate and Clopidogrel Bisulfate in Patients With Coronary Heart Disease (CHD) or CHD Equivalents (PHASE4)
- Clopidogrel Bioequivalence Study in Healthy Subjects (PHASE1)
- Patent Versus Generic Clopidogrel in Acute Coronary Syndrome (PHASE4)
- Comparative Pharmacodynamics and Pharmacokinetics Study of Generic and Reference Clopidogrel Products (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Generic clopidogrel CI brief — competitive landscape report
- Generic clopidogrel updates RSS · CI watch RSS
- Hospital Central San Luis Potosi, Mexico portfolio CI